资讯

行业新闻

与原料药、中间体及成品制剂伙伴相关的授权交易、监管决策与市场动态。

2026.07.13industry

ARPA-H Launches $160M Initiative to Scale Custom CRISPR Gene Editing for Rare Diseases

ARPA-H invests $160M in seven research teams to build scalable manufacturing for personalized CRISPR therapies, inspired by Baby KJ's success — creating new supply chain opportunities in guide RNA synthesis, lipid nanoparticles, and GMP-grade gene editing reagents.

2026.07.10industry

Roche Terminates Two Ionis-Partnered Huntington's Disease Drugs After Clinical Failures

Roche ends development of tominersen and a second antisense oligonucleotide for Huntington's disease after both programs failed, effectively closing the door on huntingtin-lowering strategies and raising questions about ASO viability in neurodegenerative diseases.

2026.07.10industry

AstraZeneca and Ionis Suffer Major Setback as Eplontersen Fails in Heart Disease Trial

Eplontersen fails to meet its primary endpoint in ATTR cardiomyopathy, reshaping the competitive landscape in favor of Alnylam and BridgeBio while raising questions about ASO therapeutics in cardiovascular indications.

2026.07.08industry

AstraZeneca, GSK Deepen China Ties with Sino Biopharm's $1.9B Respiratory Deals

Sino Biopharmaceutical strikes two landmark deals in one day: a $1.9B out-licensing agreement with AstraZeneca for COPD drug TQC3721 and expanded GSK commercialization rights in China, signaling robust cross-border pharma collaboration despite U.S. political scrutiny.

2026.07.08industry

Oberland Capital Commits $400M to MeiraGTx Eye Gene Therapies, Signaling Commercial Confidence

Specialty healthcare investor Oberland Capital provides up to $400M in non-dilutive royalty financing to MeiraGTx for late-stage gene therapy programs targeting inherited retinal diseases, reflecting growing investor confidence in gene therapy commercialization.

2026.07.07industry

FDA Approves Vera Therapeutics' Trutakna for IgA Nephropathy, Expanding Nephrology Biologics Market

FDA approves Vera Therapeutics' Trutakna for IgA nephropathy, a chronic autoimmune kidney disease, joining Novartis and Travere in a growing nephrology market that is driving demand for biologics manufacturing and specialized immunotherapy API supply.

2026.07.07industry

Kailera's Oral Obesity Pill HRS-7535 Achieves 10% Weight Loss in China Phase 3 Trial, Signaling Growing GLP-1 Competition

Kailera and Hengrui's oral GLP-1 drug HRS-7535 delivers 9.8% body weight loss over 44 weeks in a China Phase 3 trial, positioning it as a competitor to Lilly's Foundayo and Novo's Wegovy pill — though high nausea rates need optimization before global regulatory submission.

2026.07.07industry

Vertex Pharmaceuticals Acquires Crinetics for $10 Billion, Entering Endocrinology with Commercial-Stage Acromegaly Drug

Vertex Pharmaceuticals makes its largest acquisition ever with a $10B deal for Crinetics Pharmaceuticals, gaining the oral acromegaly drug Palsonify and an endocrinology pipeline with ~$5B peak sales potential, driving demand for specialized peptide and small-molecule API manufacturing.

2026.07.07industry

Novartis Enters ADC Race with $1.5B Myricx Acquisition, Bringing Novel NMTi Payload Platform

Novartis acquires U.K. biotech Myricx Bio for up to $1.5 billion, gaining two differentiated antibody-drug conjugates targeting HER2 and B7-H3 tumors with a novel N-myristoyltransferase inhibitor payload that addresses drug resistance in current ADC therapies.

2026.07.06industry

Viridian's Lumvoa Approval Reshapes Thyroid Eye Disease Market, Challenging Amgen's Tepezza

FDA approves Viridian Therapeutics' Lumvoa (veligrotug) for thyroid eye disease, creating the first direct competitor to Amgen's Tepezza with a differentiated label that analysts say provides commercial advantages, driving demand for biologics manufacturing and ophthalmology API supply.

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →